Roth MKM lowered the firm’s price target on Intuitive Machines to $4 from $12 and keeps a Buy rating on the shares. Intuitive Medicines’ Q3 revenue was impacted by the delay of its inaugural lunar launch, but the firm believes it is on track for its initial moon mission launch in early CY24 and incremental contribution from its NASA OMES contact win starting in December, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LUNR:
- Intuitive Machines price target lowered to $10 from $14 at Benchmark
- Intuitive Machines reports Q3 revenue $12.7M vs. $10.3M last year
- Intuitive Machines Reports Third Quarter 2023 Financial Results and Reaffirms Expected Launch of First Lunar Mission
- LUNR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Intuitive Machines price target lowered to $10 from $14 at Canaccord